{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:09:13Z","timestamp":1790208553935,"version":"4.1.0"},"reference-count":22,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research, Development and Innovation Office, Hungary","award":["2019-1.1.1-PIACI-KFI-2019-00194"],"award-info":[{"award-number":["2019-1.1.1-PIACI-KFI-2019-00194"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Numerous PSMA-based tracers are used for diagnostic prostate cancer imaging, but comprehensive comparisons between multiple ligands are lacking. This study aimed to compare physiological skeletal uptake and tracer uptake in commonly recommended PSMA reference regions across three different PSMA ligands in prostate cancer patients. Methods: A total of 281 prostate cancer patients were included. Using PET and SPECT imaging, target volumes of interest were defined via a semiautomatic method, and standardized uptake values (SUV) were calculated for the skeletal system and reference regions (liver, spleen, parotid gland, and blood pool). Results: Significant differences in SUV uptake were observed, with [18F]F-PSMA-1007 showing higher SUV values in the skeletal system. The parotid gland displayed the highest variability in uptake, while the blood pool and liver exhibited more homogeneous uptake across patients. Conclusions: While radioligands behave similarly in bone regions, there are notable differences in SUV patterns, particularly for PSMA-1007, which showed higher bone uptake. Parotid gland uptake variability suggests a reconsideration of its suitability as a reference region, while the liver, spleen, and blood pool showed more consistent uptake. During comparison, the technetium-labeled SPECT ligand proved as similarly effective as the two PET ligands for diagnostic imaging.<\/jats:p>","DOI":"10.3390\/ph17111458","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T06:55:37Z","timestamp":1730357737000},"page":"1458","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Different PSMA Radiopharmaceuticals: A Comparative Study of [18F]F-PSMA-1007, [18F]F-JK-PSMA-7, and [99mTc]Tc-PSMA-I&amp;S in the Skeletal System"],"prefix":"10.3390","volume":"17","author":[{"given":"Zs\u00f3fia S\u00e1ra","family":"Mik\u00f3","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5223-2053","authenticated-orcid":false,"given":"L\u00e1szl\u00f3","family":"Varga","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Farkas","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyula","family":"T\u00f3th","sequence":"additional","affiliation":[{"name":"Pozitron Diagnosztika Ltd., 1117 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krist\u00f3f","family":"Apr\u00f3","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnab\u00e1s M\u00e1rk","family":"R\u00e9v\u00e9sz","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Sipka","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter Gerg\u0151","family":"Tompa","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annam\u00e1ria","family":"Bakos","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Cz\u00e9kus","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1ty\u00e1s","family":"Bukva","sequence":"additional","affiliation":[{"name":"Department of Immunology, University of Szeged, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"P\u00e1vics","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Varga","sequence":"additional","affiliation":[{"name":"Department of Oncotherapy, University of Szeged, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2018-8413","authenticated-orcid":false,"given":"Anik\u00f3","family":"Mar\u00e1z","sequence":"additional","affiliation":[{"name":"Department of Oncotherapy, University of Szeged, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9115-9620","authenticated-orcid":false,"given":"Zsuzsanna","family":"Besenyi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Szeged, 6720 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17S","DOI":"10.2967\/jnumed.116.186775","article-title":"Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers","volume":"58","author":"Kopka","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.nucmedbio.2016.08.006","article-title":"Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer","volume":"43","author":"Pillai","year":"2016","journal-title":"Nucl. Med. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Jones, W., Griffiths, K., Barata, P.C., and Paller, C.J. (2020). PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy. Cancers, 12.","DOI":"10.3390\/cancers12061367"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"101450","DOI":"10.1016\/j.tranon.2022.101450","article-title":"Advances in PSMA theranostics","volume":"22","author":"Jeitner","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.euo.2019.01.001","article-title":"Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments","volume":"2","author":"Farolfi","year":"2019","journal-title":"Eur. Urol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2967\/jnumed.116.178939","article-title":"Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer","volume":"58","author":"Robu","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2967\/jnumed.118.215434","article-title":"Unspecific 18F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer","volume":"64","author":"Seifert","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1007\/s00259-021-05424-x","article-title":"Focal unspecific bone uptake on [18F]-PSMA-1007 PET: A multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging","volume":"48","author":"Maurer","year":"2021","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1007\/s00259-021-05456-3","article-title":"Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: A retrospective evaluation","volume":"48","author":"Arnfield","year":"2021","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00259-023-06424-9","article-title":"The potential role of osteoporosis in unspecific [18F]PSMA-1007 bone uptake","volume":"51","author":"Ninatti","year":"2023","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13550-020-00635-z","article-title":"[99cmTc]Tc-PSMA-I&S-SPECT\/CT: Experience in prostate cancer imaging in an outpatient center","volume":"10","author":"Werner","year":"2020","journal-title":"EJNMMI Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"17588359231221342","DOI":"10.1177\/17588359231221342","article-title":"Diagnostic value of [99mTc]Tc-PSMA-I&S-SPECT\/CT for the primary staging and restaging of prostate cancer","volume":"16","author":"Farkas","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/pros.23444","article-title":"99mTc-MIP-1404-SPECT\/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer","volume":"78","author":"Schmidkonz","year":"2018","journal-title":"Prostate"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/pros.23696","article-title":"Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT\/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy","volume":"78","author":"Liu","year":"2018","journal-title":"Prostate"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1097\/RLU.0000000000003410","article-title":"99mTc-PSMA SPECT\/CT Versus 68Ga-PSMA PET\/CT in the Evaluation of Metastatic Prostate Cancer","volume":"46","author":"Fallahi","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_16","first-page":"241890","article-title":"99mTc-PSMA-I&S radioguided salvage lymphadenectomy for prostate cancer: Preliminary clinical results from a prospective trial","volume":"65","author":"Ells","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: Joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: The EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.2967\/jnumed.122.265242","article-title":"PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study","volume":"64","author":"Hotta","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Arndt, C., Bergmann, R., Striese, F., Merkel, K., M\u00e1th\u00e9, D., Loureiro, L.R., Mitwasi, N., Kegler, A., Fasslrinner, F., and Gonz\u00e1lez Soto, K.E. (2022). Development and Functional Characterization of a Versatile Radio-\/Immunotheranostic Tool for Prostate Cancer Management. Cancers, 14.","DOI":"10.3390\/cancers14081996"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2967\/jnumed.116.181768","article-title":"Preclinical Evaluation of 18F-PSMA-1007.; a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging","volume":"58","author":"Cardinale","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Cardinale, J., Martin, R., Remde, Y., Sch\u00e4fer, M., Hienzsch, A., H\u00fcbner, S., Zerges, A.M., Marx, H., Hesse, R., and Weber, K. (2017). Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer. Pharmaceuticals, 10.","DOI":"10.20944\/preprints201708.0057.v1"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/11\/1458\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:25:03Z","timestamp":1760113503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/11\/1458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["ph17111458"],"URL":"https:\/\/doi.org\/10.3390\/ph17111458","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}